profit from every $100 of sales.
$0$100
Innoviva
$19.00-0.52% today
-8.9% in 1 year
1-year low $19.001-year high $24.24
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $4.98 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Innoviva sold, what it kept, and what it did with the cash.
Sales went from $331 million in 2022 to $411 million in 2025, with $271 million of profit last year.
SalesProfit
Innoviva handed back 3% of the cash it generated last year.
Buybacks $5M
Free cash flow 2025$186M
Bought back its own shares$5M
Paid as dividends–
Cash vs. debt$551M vs. $269M
Innoviva vs. similar companies
Innoviva grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Innoviva | 5.0× · Cheap | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Innoviva's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 331 | 310 | 359 | 411 | |
| 318 | 268 | 322 | 334 | |
| 207 | 114 | 167 | 164 | |
| 308 | 235 | 85 | 370 | |
| 214 | 180 | 23 | 271 | |
| 2.37 | 2.20 | 0.36 | 3.30 | |
| 95.8% | 86.3% | 89.8% | 81.2% | |
| 62.5% | 36.7% | 46.5% | 39.8% | |
| 64.6% | 57.9% | 6.5% | 65.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,231 | 1,244 | 1,301 | 1,635 |
| Cash | 291 | 194 | 305 | 551 |
| Total debt | 544 | 449 | 451 | 269 |
| Total liabilities | 666 | 569 | 610 | 462 |
| 566 | 675 | 691 | 1,173 | |
| 95 | 87 | 74 | 85 | |
| 21.5% | 15.0% | 4.1% | 18.8% | |
| 37.8% | 26.6% | 3.4% | 23.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 202 | 141 | 189 | 197 | |
| 0 | 0 | 4 | 10 | |
| 202 | 141 | 184 | 186 | |
| Dividends paid | – | – | – | – |
| 9 | 76 | 15 | 5 | |
| 7 | 6 | 6 | 9 |
Valuation
- 5.0×
- 9.9×
- 0.43
- 1.2×
- 3.3×
- 7.2×
- 2.9×
- 13.8%
- 20.1%
- 0.0%
Profitability
- 81.2%
- 39.8%
- 65.9%
- 105.9%
- 2.9%
- 17.8%
- 47.6%
- 27.5%
- 3.5%
- 7.4%
Growth
- +7.5%
- +11.7%
- +3.9%
- –
- −4.8%
Financial health
- -0.6×
- 0.25
- 18.0%
- 9.6×
- 21.13
- 20.07
- 0.23
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 43%of 948
Top 4%of 871
Top 3%of 560
Bottom 37%of 868
Top 4%of 985
What analysts expect
- Average price target
- $37.67
- Range
- $32.00 – $46.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.44 | 0.43 | +2.3% |
| Feb 25, 2026 | 1.94 | 0.34 | +470.6% |
| Nov 5, 2025 | 1.08 | 0.46 | +134.8% |
| Aug 6, 2025 | 0.77 | 0.57 | +35.1% |
| May 7, 2025 | 0.25 | 0.29 | −13.8% |
| Feb 26, 2025 | 0.57 | 0.34 | +67.6% |
| Nov 6, 2024 | 0.02 | 0.27 | −92.6% |
| Jul 31, 2024 | 0.68 | 0.24 | +183.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
7/7Passes 7 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
83Pass
Benjamin Graham
99Pass
Philip Fisher
88Pass
Peter Lynch
78Pass
Joel Greenblatt
68Pass
Charlie Munger
86Pass
Terry Smith
75Pass
Questions about Innoviva
Is Innoviva a good stock to buy?
A strong, very profitable business, and the price looks low. 7 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Innoviva AI analysis
What does Innoviva do?
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. It is in Biotechnology.
Does Innoviva pay a dividend?
No. Innoviva does not pay a dividend at the moment; in 2025 it returned $4.68 million to shareholders by buying back its own shares.
Is Innoviva stock halal?
No. Innoviva does not pass our halal screen: its cash and confirmed interest-bearing investments are 41% of its market value, at or above the 33% limit. How we check
How has Innoviva stock done over the past year?
Down 8.9% over the past twelve months, to $19.00. It traded between $19.00 and $24.24 and is 21.6% below its high.
Who are Innoviva's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Innoviva's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.